Table 2.
Characteristics of included studies: Vitamin D treatment and evaluating bone health in children with inflammatory bowel disease
| Study | N1 | Location | Design | Treatment Regimen |
Vitamin D levels2 |
Main study outcome | Disease activity3 | |
| Baseline | Follow-up | |||||||
| Hradsky, 2017 | 55 (IBD) | Czech Republic | Cohort | 2000 IU/d D3 | 23.2 (17.2, 31.6) | 34 (24.4, 38.4) | Effect of vitamin D on trabecular BMD and muscle power | 5 (0-10) |
| Benchimol, 2007 | 72 (IBD) | North America | Prospective | A: no intervention; B: supplemental calcium or supplemental calcium & 50000 IU/m D2 | A: 27.6; B: 22.8 ± 8 or 24.4 ± 6 | B: 26.4 ± 6 or 30 ± 12 | Effect of vitamin D on lumbar spine BMD | A: 10.6 ± 10.6; B: 16.5 ± 15.7 |
| Leonard, 2016 | 121 (CD) | United States | RCT | A: 10 min LMMS/d; B: no LMMS (both 600 IU/d D3) | 31.5 ± 10.3 | 34.2 ± 12.4 (12 m); 37.7 ± 15.6 (24 m)4 | Effect of LMMS on BMD | < 10:52; 10-30:33; > 30:5 |
| Laakso, 2014 | 47 (IBD) | Finland | Cohort | Total vitamin D intake: 7.5 (1.6-19.5) μg/d (baseline); 12.6 (1.7-49.2) μg/d (follow-up) | 19.6 (8.6, 40.8) | 26.8 (10.4, 48) | BMD and BMC | < 10:72; 10-30:23; > 30:4 |
1
Number of patients recruited (type of disease);
2
Serum levels expressed as mean ± SD, mean and interquartile range, or mean;
3
Disease activity scores (Pediatric Crohn disease activity index or Pediatric ulcerative colitis disease activity index) at baseline expressed as mean (range), mean ± SD or percentage of patients with score less than 10, 10-30, or > 30;
4
Calculated in 105 patients who completed the trial. IBD: Inflammatory bowel disease; CD: Crohn disease; UC: Ulcerative colitis; BMD: Bone mineral density; LMMS: Low magnitude mechanical stimulation; BMC: Bone mineral content.